DTR: Year-End Portfolio Review & Outlook
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
Atomera Inc. (ATOM) is set to report Q3 results today. Here’s why the comapny remains the best risk versus reward investment. Period.
Every major tech company is working on augmented reality. This micro-cap pioneer owns all the key patents and is already ramping up sales, making it an obvious takeover target
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
Artificial intelligence and biotech are the two hottest trends to invest in right now and we’ve found a single micro-cap positioned to profit from both…
Only 30 days after I pegged TFF Pharmaceuticals, Inc. (TFFP) as the next potential multi-billion-dollar biotech platform, management just delivered.
Biotech is THE sector to invest in right now and we’ve found the next micro-cap with multi-billion-dollar platform potential…
Analysts and insiders getting more bullish about Provention Bio (PRVB) and another strong rally for Atomera (ATOM) as Russell 2000 rebalance approaches
The week started off with a flurry of data and developments from Cue Biopharma (CUE) and Provention Bio (PRVB), along with a rally for Atomera (ATOM)
Provention Bio (PRVB) successfully priced a $100 million offering. Here are all the details, along with three key data takeaways from the ADA meeting…